Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Viridian Therapeutics Inc (VRDN)

Viridian Therapeutics Inc (VRDN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,478,935
  • Shares Outstanding, K 102,207
  • Annual Sales, $ 70,850 K
  • Annual Income, $ -342,600 K
  • EBIT $ -363 M
  • EBITDA $ -370 M
  • 60-Month Beta 1.16
  • Price/Sales 20.14
  • Price/Cash Flow N/A
  • Price/Book 2.26

Options Overview Details

View History
  • Implied Volatility 96.99% (-7.99%)
  • Historical Volatility 146.05%
  • IV Percentile 46%
  • IV Rank 26.29%
  • IV High 214.65% on 03/20/26
  • IV Low 55.02% on 08/08/25
  • Expected Move (DTE 8) 1.19 (7.75%)
  • Put/Call Vol Ratio 0.36
  • Today's Volume 174
  • Volume Avg (30-Day) 1,361
  • Put/Call OI Ratio 4.14
  • Today's Open Interest 28,342
  • Open Int (30-Day) 12,277
  • Expected Range 14.16 to 16.54

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.05
  • Number of Estimates 7
  • High Estimate $-0.95
  • Low Estimate $-1.20
  • Prior Year $-0.87
  • Growth Rate Est. (year over year) -20.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.33 +15.15%
on 04/07/26
30.42 -49.54%
on 03/10/26
-14.30 (-48.23%)
since 03/09/26
3-Month
13.33 +15.15%
on 04/07/26
34.29 -55.23%
on 01/14/26
-16.40 (-51.65%)
since 01/09/26
52-Week
10.79 +42.26%
on 04/10/25
34.29 -55.23%
on 01/14/26
+3.56 (+30.20%)
since 04/09/25

Most Recent Stories

More News
Stocks Pressured by Economic Fallout from Iran War

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.39%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.78%. June E-mini...

AMAT : 394.41 (+2.25%)
SNDK : 832.87 (+6.66%)
INTU : 362.96 (-6.53%)
$IUXX : 25,020.64 (+0.47%)
LITE : 885.84 (-1.14%)
UTHR : 579.45 (-0.39%)
ASML : 1,443.17 (+1.56%)
ZNM26 : 111-135 (+0.17%)
GLW : 169.90 (+2.91%)
ESM26 : 6,857.00 (+0.49%)
STX : 499.21 (+0.59%)
WDC : 336.93 (-0.55%)
Markets Turn Negative as Crude Oil Prices Surge

The S&P 500 Index ($SPX ) (SPY ) today is down -0.75%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.21%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.18%. Stock indexes turned lower...

AMAT : 394.41 (+2.25%)
AVGO : 357.50 (+1.96%)
INTU : 362.96 (-6.53%)
DDOG : 110.67 (-5.00%)
EXPE : 230.33 (-2.77%)
$IUXX : 25,020.64 (+0.47%)
UTHR : 579.45 (-0.39%)
ASML : 1,443.17 (+1.56%)
ZNM26 : 111-135 (+0.17%)
CLK26 : 97.55 (+3.33%)
STX : 499.21 (+0.59%)
WDC : 336.93 (-0.55%)
Stocks Rebound as T-note Yields Tumble

The S&P 500 Index ($SPX ) (SPY ) today is up +0.42%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.32%. June E-mini S&P futures (ESM26...

MSTR : 130.04 (+1.36%)
INTU : 362.96 (-6.53%)
DDOG : 110.67 (-5.00%)
GLXY : 20.79 (+9.42%)
EXPE : 230.33 (-2.77%)
$IUXX : 25,020.64 (+0.47%)
COIN : 171.77 (-1.90%)
UTHR : 579.45 (-0.39%)
ZNM26 : 111-135 (+0.17%)
ESM26 : 6,857.00 (+0.49%)
$DOWI : 48,157.81 (+0.52%)
^BTCUSD : 71,862.05 (+0.67%)
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease

- REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved...

VRDN : 15.53 (+7.33%)
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

   - PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. commercial preparations on track to support anticipated launch - ...

VRDN : 15.53 (+7.33%)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced...

VRDN : 15.53 (+7.33%)
Viridian Therapeutics Prepares for Transformational 2026

- Veligrotug BLA accepted for thyroid eye disease (TED) with PDUFA target action date of June 30, 2026 under Priority Review; commercial preparations on track - - Topline...

VRDN : 15.53 (+7.33%)
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease

- PDUFA target action date of June 30, 2026 - - Priority Review designation is granted to applications for drugs that, if approved, would be a significant improvement...

VRDN : 15.53 (+7.33%)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced...

VRDN : 15.53 (+7.33%)
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced...

VRDN : 15.53 (+7.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Relative Strength is below 30%. The market is in oversold territory. Watch for a potential trend reversal.

See More Share

Business Summary

Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.

See More

Key Turning Points

3rd Resistance Point 15.53
2nd Resistance Point 15.02
1st Resistance Point 14.75
Last Price 15.53
1st Support Level 13.97
2nd Support Level 13.46
3rd Support Level 13.19

See More

52-Week High 34.29
Fibonacci 61.8% 25.31
Fibonacci 50% 22.54
Fibonacci 38.2% 19.77
Last Price 15.53
52-Week Low 10.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.